InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

InspireMD Stock Performance

NYSE NSPR opened at $2.27 on Tuesday. The company has a market capitalization of $53.25 million, a P/E ratio of -2.10 and a beta of 0.84. InspireMD has a one year low of $0.96 and a one year high of $3.85. The stock has a 50 day moving average price of $2.49 and a 200-day moving average price of $2.74.

InspireMD (NYSE:NSPR) last posted its earnings results on Wednesday, March 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The firm had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.65 million. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. During the same period in the prior year, the company earned ($0.60) EPS. As a group, equities analysts predict that InspireMD will post -0.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. McKinley Carter Wealth Services Inc. purchased a new stake in InspireMD during the 4th quarter valued at $28,000. Renaissance Technologies LLC purchased a new stake in InspireMD in the second quarter worth $36,000. Avestar Capital LLC purchased a new stake in InspireMD in the third quarter worth $65,000. Northern Trust Corp purchased a new stake in InspireMD in the fourth quarter worth $80,000. Finally, Marshall Wace LLP purchased a new stake in InspireMD in the second quarter worth $4,670,000. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions.